[HTML][HTML] SARS-CoV-2 Omicron variant: recent progress and future perspectives
Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, there have been
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …
a few variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of …
Covid-19 vaccines—immunity, variants, boosters
DH Barouch - New England Journal of Medicine, 2022 - Mass Medical Soc
Covid-19 Vaccines — Immunity, Variants, Boosters | New England Journal of Medicine Skip to
main content The New England Journal of Medicine homepage Advanced Search SEARCH …
main content The New England Journal of Medicine homepage Advanced Search SEARCH …
BA. 2.12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages BA.
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage. The receptor …
2.12. 1, BA. 4 and BA. 5 exhibit higher transmissibility than the BA. 2 lineage. The receptor …
[HTML][HTML] Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …
due to altered antibody evasion properties deriving from their additional spike mutations …
Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4 and BA. 5
Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …
become dominant in the United States and South Africa, respectively,. These new …
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
Continuous evolution of Omicron has led to a rapid and simultaneous emergence of
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …
numerous variants that display growth advantages over BA. 5 (ref.). Despite their divergent …
Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19
MJ Levin, A Ustianowski, S De Wit… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
Efficacy of antiviral agents against omicron subvariants BQ. 1.1 and XBB
M Imai, M Ito, M Kiso, S Yamayoshi… - … England Journal of …, 2023 - Mass Medical Soc
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB | New England Journal
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …
Efficacy of antibodies and antiviral drugs against Omicron BA. 2.12. 1, BA. 4, and BA. 5 subvariants
E Takashita, S Yamayoshi, V Simon… - … England Journal of …, 2022 - Mass Medical Soc
Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5
Subvariants | New England Journal of Medicine Skip to main content The New England Journal …
Subvariants | New England Journal of Medicine Skip to main content The New England Journal …
Evolution of the SARS‐CoV‐2 omicron variants BA. 1 to BA. 5: implications for immune escape and transmission
The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …